Inhibitors of the SMAD2/3 pathway have also been explored for treatment of PAH (Table 1) and could theoretically be used in combination with activators of the SMAD1/5/8 pathway as a strategy to rebalance superfamily signaling. This evidence concerns the gene SMAD1 and pulmonary arterial hypertension.